Karyopharm Therapeutics

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Average True Range

Score

0.9

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 2 181.0 0.50% 1.00% 56.6% -0.3% 56.3%
SHORT 2 126.5 0.50% 1.00% 85.7% -10.4% 75.3%

Summary

Technical Analysis

Karyopharm Therapeutics has a TR of 0.62, and an ATR(14) of 0.573.



Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.

Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]


PROFILE: Karyopharm Therapeutics (KPTI)


Stock Exchange: NASDAQ
Company: Karyopharm Therapeutics
Ticker Codes: | KPTI | NASDAQ:KPTI |

About Karyopharm Therapeutics (NASDAQ:KPTI):

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Top 10:

Average True Range

Download
Company Close Change(%) Volume Value Signal
NYNY Empire Resorts Inc 9.68 14.6 187,517 0.68 NEUTRAL
DHXM DHX Media Ltd 1.27 12.4 234,932 0.11 NEUTRAL
MCRB Seres Theraptc 3.31 11.4 277,629 0.25 NEUTRAL
TUSK Mammoth Energy Services 4.34 9.6 253,268 0.44 NEUTRAL
BCOM B Communications 1.34 8.1 4,721 0.1 NEUTRAL
NVDA Nvidia Corporation 170.94 7.1 17,914,275 6.6 NEUTRAL
ACIU AC Immune 5.73 6.9 146,621 0.3 NEUTRAL
ACRS Aclaris Therapts 0.93 6.5 1,250,572 0.15 NEUTRAL
NNBR Nn Inc 6.45 6.4 110,947 0.52 NEUTRAL
WYNN Wynn Resorts 112.41 6.3 2,922,585 4.88 NEUTRAL